News Releases
EPA Product Epadel S900 Set to Offer New Dose and
Innovative Stick-Type Packaging Beginning July 12th
(Tokyo, July 8, 2004) - Mochida Pharmaceutical Co., Ltd. (President: Naoyuki Mochida) is set to launch its new Epadel S900 (900 mg/pack) on July 12, representing an all-new package design and dose for Epadel, a therapeutic agent for the treatment of arteriosclerosis obliterans and hyperlipidemia, and Mochida's core product line.
Epadel S900 joins the products ranks of Epadel S300 (300 mg/pack) and Epadel S600 (600 mg/pack) containing conventional doses, as well as the Epadel Capsules in capsule form. The addition of the new 900 mg/pack is aimed at helping patients to take it easily, since the dosage may be increased up to 900 mg t.i.d. for the effective treatment of hyperlipidemia, particularly when the patient has abnormal triglyceride levels.
This innovative stick-type package is clearly different from existing lines. The package design give a clear indication of its perforated tab and cut direction, and was designed with the patients' convenience in mind, adding innovations such as rounded corners to eliminate finger cuts when opening.
With the cooperation of Nippon Suisan, Epadel was launched in 1990 with approval for arteriosclerosis obliterans, marking the appearance of the world's first high-purity ethyl icosapentate preparation. In 1994, the drug was further approved for hyperlipidemia, earning acclaim as the only EPA product approved by clinicians for its effect on hyperlipidemia. The "Japan EPA Lipid Intervention Study (JELIS)" (an intervention study assessing cardiovascular accidents, cardiovascular deaths and total mortality) is an ongoing randomized controlled study involving more than 18,000 patients with hyperlipidemia. Results are expected following analysis.